“"People with POTS often also have autoimmune diseases, and similar immune-related connections are emerging in long COVID, with evidence suggesting the immune system may disrupt nerves that regulate functions like heart rate and digestion, though experts don't classify either POTS or long COVID as autoimmune disorders themselves"”

• Where would you place this on a scale from false to accurate, and why?
• What would you need to see to be sure? Who would have the original evidence?
• Which words in the claim are doing the most work?

This National Geographic post is mostly accurate. The article is real, and the science behind it checks out. Research consistently finds that roughly 16 to 20 percent of people with POTS also have a diagnosed autoimmune disease, which is meaningfully higher than the general population, and antibodies that target nerve receptors controlling heart rate and blood vessels have been found in POTS patients by several research groups. Similar antibody research is underway in long COVID, where a 2025 systematic review found most studies reported some association but with a lot of inconsistency between them. The post is right that experts do not classify either condition as an autoimmune disease, and the official expert consensus states that a causal role for these antibodies has not been established. Two caveats the post leaves out: one study found the widely used commercial antibody tests could not tell POTS patients apart from healthy people, and the only randomized trial of immune treatment for POTS did not show benefit. The word "often" slightly oversells a rate that still leaves about four in five POTS patients without an autoimmune diagnosis.

• POTS patients do have elevated rates of diagnosed autoimmune disease relative to the general population (16 to 20 percent), confirmed across at least three independent datasets.
• Elevated non-specific autoimmune markers (ANA, antiphospholipid antibodies) are documented in POTS cohorts.
• Autoantibodies targeting adrenergic and muscarinic receptors have been reported in POTS by multiple labs, and an animal model has reproduced a POTS-like phenotype.
• Autoantibody associations are being actively studied in long COVID, with a majority of studies reporting some association.
• The classification qualifier is accurate. Expert consensus explicitly states causality is not established, and neither condition is classified as an autoimmune disease.
• The caption's hedged language ("may play a role," "evidence suggests," "researchers are now looking for") is appropriate to the evidence level.
• The National Geographic article and photo credit are real.

• **Word choice on "often" (mild exaggeration).** "Often also have autoimmune diseases" describes a rate of 16 to 20 percent. That is a real and statistically meaningful elevation, but it means roughly four out of five POTS patients do not have a diagnosed autoimmune disease. "Often" invites a reader to assume a majority. "More commonly than the general population" would be precise.
• **Omitted counterevidence (selective framing).** The caption presents the autoantibody hypothesis as a promising active research frontier without mentioning that the most widely cited commercial autoantibody tests failed a direct head-to-head validation against healthy controls, or that the single randomized immunotherapy trial was negative. This is a standard feature of science-promotion captions rather than a factual error, but it does leave a rosier impression than the field warrants.
• **Implied equivalence between POTS and long COVID evidence.** "Similar connections are emerging in long COVID" compresses a substantially more heterogeneous and conflicting body of evidence into parity with the POTS literature.

• Whether any autoantibody is causal rather than a bystander marker. Expert consensus says this is unresolved.
• Whether the autoantibodies found in POTS and long COVID are disease-specific. They also appear in ME/CFS, small fiber neuropathy, complex regional pain syndrome and, at varying levels, in healthy people.
• Whether autoantibody-directed treatment will work. The evidence base is currently one negative RCT plus uncontrolled case series.
• The full text of the National Geographic article was not retrieved in its entirety (paywall), so I verified the caption against the article's headline, deck, and opening section plus the independent scientific literature, not against every sentence of the article. ---

• **NIH Expert Consensus Meeting on POTS, Part 1 (Vernino et al., *Autonomic Neuroscience*, 2021)** (primary)
  https://www.sciencedirect.com/science/article/pii/S1566070221000588
• **Hall et al. (2022), PubMed 35766055, commercial GPCR autoantibody ELISA validation study** (primary)
  https://pubmed.ncbi.nlm.nih.gov/35766055/
• **Blitshteyn (2015), *Lupus*, autoimmune markers in POTS** (primary)
  https://doi.org/10.1177/0961203315587566
• **"Autoantibodies in long COVID: a systematic review," *Lancet Infectious Diseases* (Sept 2025)** (primary)
  https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00411-6/
• **Cleveland Clinic Journal of Medicine (2023), "Autoimmunity and POTS"** (secondary)
  https://www.ccjm.org/content/90/7/439
• **Blitshteyn et al., "Autoimmunity in POTS: Current understanding," *Autonomic Neuroscience*** (secondary)
  https://www.sciencedirect.com/science/article/abs/pii/S1566070218300134
• **Li et al., "Autoimmune Basis for Postural Tachycardia Syndrome," *JAHA* 2014** (primary)
  https://www.ahajournals.org/doi/10.1161/jaha.113.000755
• **Vernino et al., iSTAND RCT of IVIG in autoimmune POTS, *Clin Auton Res* 2024** (primary)
• **National Geographic, "Why Do POTS and Long COVID Look So Much Like Autoimmune Disorders?"** (secondary)
  https://www.nationalgeographic.com/health/article/pots-long-covid-autoimmune